Arcus Biosciences (RCUS) Tops Q4 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
H.C. Wainwright Upgrades Arcus Biosciences (RCUS) to Buy
February 26, 2025 6:06 AM ESTH.C. Wainwright analyst Emily Bodnar upgraded Arcus Biosciences (NYSE: RCUS) from Neutral to Buy with a price target of $24.00.
The analyst comments "Initial cas + cabo data expected in mid-2025; we are increasingly positive on opportunity given cas efficacy vs belzutifan. The ARC-20 study evaluating casdatifan (cas) monotherapy and in combo with other agents in clear cell renal cell carcinoma (ccRCC) has enrolled ~40 patients in the cas + cabozantinib (cabo) cohort, which is meant to evaluate the same combo and patient population as the Phase 3 PEAK-1 study expected to initiate in 2Q25... More
